Fri Oct 04 05:45:00 UTC 2024: ## Recordati Acquires Global Rights to Enjaymo® for Treatment of Rare Blood Disorder

**Milan, October 4, 2024** – Recordati, an international pharmaceutical group, announced today that they have entered into an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), the only approved targeted treatment for cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.

Enjaymo® is a humanized monoclonal antibody indicated for treating hemolysis in adults with CAD. It was granted approval by the FDA, the European Commission, and the Japanese Ministry of Health, Labor and Welfare in 2022. As a chronic IV treatment, Enjaymo® addresses a significant unmet need for patients with CAD.

The acquisition will cost Recordati an upfront payment of US$825 million and additional milestone payments of up to US$250 million, contingent on reaching specific sales thresholds. The deal is expected to close by the end of 2024, pending regulatory approvals.

Enjaymo® generated approximately €100 million in revenue over the last 12 months, with projections exceeding €150 million in FY 2025 and peak sales potential reaching €250-300 million. The transaction is anticipated to be immediately accretive at the EBITDA level, with margins exceeding the current Rare Diseases average by 2025.

Rob Koremans, CEO of Recordati, stated, “This acquisition aligns with our broader strategy, reinforces our commitment to Rare Diseases, and complements our Oncology portfolio, particularly Sylvant®. Enjaymo® expands our Rare Diseases footprint in the U.S., Japan, and Europe, contributing positively to both our top and bottom lines. Notably, Enjaymo® addresses a critical unmet medical need for patients living with this debilitating disease.”

CAD is a rare disorder affecting approximately 11,000 patients in the U.S., Japan, and Europe. It is characterized by debilitating fatigue and other anemic symptoms that significantly impact quality of life. Enjaymo® targets and inhibits C1s in the classical complement pathway, preventing the abnormal destruction of healthy red blood cells.

Recordati will host a conference call today at 13:00 CEST (12:00 p.m. GMT) to discuss the acquisition of Enjaymo®. The call details are available on Recordati’s website.

Read More